Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score

BACKGROUND: Immunohistological assessment of Ki 67 expression is less expensive than Oncotype Dx, which is currently used to identify patients with lymph node-negative breast cancer, who will benefit from adjuvant chemotherapy. METHODS: The relationship of immunohistologically measured Ki 67 to Onco...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahebjam, S, Aloyz, R, Pilavdzic, D, Brisson, M-L, Ferrario, C, Bouganim, N, Cohen, V, Miller, W H, Panasci, L C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241562/
https://www.ncbi.nlm.nih.gov/pubmed/21970880
http://dx.doi.org/10.1038/bjc.2011.402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241562/
https://www.ncbi.nlm.nih.gov/pubmed/21970880
http://dx.doi.org/10.1038/bjc.2011.402

Ejemplares similares